Generic HIV Prevention Shot Gains FDA Approval
Lenacapavir's twice-a-year injection could reach some low- and middle-income countries within weeks at about $40 a year.
Updated on Nov. 2, 2026 in Sexual Health
Live Poll
Do you think affordable HIV prevention drugs should be a public health priority?
The FDA approved a generic version of lenacapavir, Gilead Sciences' twice-a-year injectable for HIV prevention, a move that opens the door to lower-cost supply in low- and middle-income countries. Generic lenacapavir is expected to reach some of those countries within weeks, though it cannot be sold in the United States while the brand-name version remains under patent.
Why it matters
Demand for lenacapavir has outstripped supply in low- and middle-income countries, and the approval could ease that bottleneck for people who need HIV prevention. FDA approval can also speed regulatory decisions in other countries, which may shorten the time before the shot reaches clinics abroad.
The approval rests on FDA review of a generic product developed by Dr. Reddy's Laboratories under an agreement brokered by Unitaid, the Clinton Health Access Initiative and Wits RHI. The FDA approval is tentative because the originator product remains under patent, and the projected $40 annual cost is an estimate rather than a finalized price.
The players
Gilead Sciences
A biopharmaceutical company focused on HIV, liver disease and oncology, and the developer of the brand-name lenacapavir treatment Yeztugo.
Dr. Reddy's Laboratories
An Indian pharmaceutical company that developed the generic version of lenacapavir under the brokered agreement.
Unitaid
A global health agency that works to speed access to HIV, tuberculosis and malaria tools in low- and middle-income countries.
Clinton Health Access Initiative
A global health organization that works on HIV and other diseases by strengthening health systems and negotiating lower drug prices.
The details
Lenacapavir works as a long-acting preventive injection given twice a year, which is why it is described as the world's only twice-a-year shot to prevent HIV. The generic was approved under a longstanding FDA practice designed to ensure the quality of HIV-related drugs supplied to other countries through U.S. government programs. People must be tested for HIV before starting lenacapavir and again with each injection, and common side effects include injection site reactions, headache and nausea.
Timeline
Last year: Gilead Sciences established royalty-free licensing agreements with six generic manufacturers, and brand-name Yeztugo was approved.
Monday morning: The manufacturer and partner organizations announced the FDA approval of the generic version.
Within weeks: Generic lenacapavir is expected to start becoming available in some low- and middle-income countries.
Health Landscape
Generic HIV drugs approved under the FDA's tentative-approval practice have long been central to U.S.-funded global treatment programs. Lenacapavir extends that model to long-acting prevention, a segment where licensing deals with generic makers aim to close the gap between supply and demand.
If you are at risk of HIV, this development expands the set of prevention options you may eventually be able to access, especially in regions where the drug is entering the market. Anyone considering a preventive injection should talk with a clinician about HIV testing requirements and whether a long-acting option fits their situation.
The takeaway
A twice-a-year HIV-prevention shot moving toward lower-cost generic supply is a meaningful shift for global prevention access. Readers interested in prevention options should ask a clinician about HIV testing and whether a long-acting option is appropriate for them.
Further reading
For background on how HIV prevention tools reach people, explore our Sexual Health coverage.
Live Poll
Do you think affordable HIV prevention drugs should be a public health priority?
